Letters to the Editor
Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?
Z. Layegh1, F. Hooijberg2, C. Bastida3, A.D. Huitema4, T. Rispens5, C.G. Wolbink6
- Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. zohralayegh@gmail.com
- Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
- Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, and Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
CER14606
2022 Vol.40, N°3
PI 0664, PF 0665
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 34796848 [PubMed]
Received: 04/03/2021
Accepted : 14/06/2021
In Press: 03/11/2021
Published: 22/03/2022
